← Leaderboards
Tuomas Tammela
Sloan-Kettering Inst Can Research
$7,490,282
Attributed
$9,287,050
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.2M · FY2014–25$5M$3.8M$2.5M$1.3M$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,287,050 · 7
By mechanism
R01$5,370,768 · 4
R37$2,913,746 · 1
R00$756,790 · 1
K99$245,746 · 1
Top collaborators
- Michael Hemann2 shared
- Kwok Kin Wong2 shared
- Lydia Finley1 shared
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Luc Gordon Trang Morris$1,605,886
- Hikmat Al-Ahmadie$4,559,862
- Jessica Rios$111,927
- Richard N Kolesnick$17,601,323
- Marcus A. Ruscetti$1,704,238
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoResponseTumorCellsCancer CellMolecularGeneticMalignant NeoplasmsChemotherapyTumor ProgressionPhenotypeHeterogeneityLung AdenocarcinomaAblationReporterGene ExpressionGenetically Engineered MouseSignal PathwayCancer TherapyAllelesGene Expression ProfilingSignal TransductionProgramsStem Cells
Grant awards (19)
Metabolic control of malignant fates in lung cancer$730,400
R01 · FY2025 · CA
Targeting cell state transitions driving resistance to KRAS inhibitors in lung cancer$718,258
R01 · FY2025 · CA
Investigating hypoxia as a determinant of malignant fates in pancreas cancer$695,122
R01 · FY2025 · CA · contact PI
Targeting plasticity in lung cancer$611,289
R01 · FY2025 · CA · contact PI
Targeting stem-like cells and their niche in pancreatic cancer$490,849
R37 · FY2025 · CA · contact PI
Targeting cell state transitions driving resistance to KRAS inhibitors in lung cancer$735,635
R01 · FY2024 · CA
Investigating hypoxia as a determinant of malignant fates in pancreas cancer$714,122
R01 · FY2024 · CA · contact PI
Targeting plasticity in lung cancer$582,097
R01 · FY2024 · CA · contact PI
Targeting stem-like cells and their niche in pancreatic cancer$463,044
R37 · FY2024 · CA · contact PI
Targeting plasticity in lung cancer$583,845
R01 · FY2023 · CA · contact PI
Targeting stem-like cells and their niche in pancreatic cancer$477,667
R37 · FY2023 · CA · contact PI
Targeting stem-like cells and their niche in pancreatic cancer$487,415
R37 · FY2022 · CA · contact PI
Targeting stem-like cells and their niche in pancreatic cancer$504,203
R37 · FY2021 · CA · contact PI
Targeting stem-like cells and their niche in pancreatic cancer$490,568
R37 · FY2020 · CA · contact PI
Investigating cellular heterogeneity in lung cancer$258,798
R00 · FY2019 · CA · contact PI
Investigating cellular heterogeneity in lung cancer$248,992
R00 · FY2018 · CA · contact PI
Investigating cellular heterogeneity in lung cancer$249,000
R00 · FY2017 · CA · contact PI
Investigating Wnt and Lgr5 signaling as regulators of lung cancer heterogeneity$122,873
K99 · FY2015 · CA · contact PI
Investigating Wnt and Lgr5 signaling as regulators of lung cancer heterogeneity$122,873
K99 · FY2014 · CA · contact PI